We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+4.43%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$956M
AUM Growth
+$110M
Cap. Flow
+$88M
Cap. Flow %
9.21%
Top 10 Hldgs %
34.18%
Holding
136
New
4
Increased
63
Reduced
26
Closed
5

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$10.5M
2
ALGN icon
Align Technology
ALGN
+$9.68M
3
CELG
Celgene Corp
CELG
+$9.59M
4
ELV icon
Elevance Health
ELV
+$9.1M
5
COR icon
Cencora
COR
+$7.21M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$7.35M
2
CI icon
Cigna
CI
+$4.96M
3
BCR
CR Bard Inc.
BCR
+$4.65M
4
CNC icon
Centene
CNC
+$4.38M
5
ALKS icon
Alkermes
ALKS
+$4.36M

Sector Composition

Rank Sector Weight
1 Healthcare 94.19%
2 Financials 0.94%
3 Industrials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRC
26
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$12.6M 1.32%
169,939
+65,436
+63% +$5.04M
ALXN
27
DELISTED
Alexion Pharmaceuticals
ALXN
$12.1M 1.26%
86,000
-6,000
-7% -$815K
SYK icon
28
Stryker
SYK
$123B
$12M 1.25%
84,300
– –
CNC icon
29
Centene
CNC
$32.8B
$11.5M 1.2%
237,860
-101,760
-30% -$4.38M
LIVN icon
30
LivaNova
LIVN
$4.43B
$11.1M 1.16%
158,069
+55,261
+54% +$3.5M
ZBH icon
31
Zimmer Biomet
ZBH
$17.6B
$10.9M 1.14%
95,790
+5,150
+6% +$594K
BDX icon
32
Becton Dickinson
BDX
$43.6B
$10.8M 1.13%
56,375
+3,075
+6% +$596K
TEVA icon
33
Teva Pharmaceuticals
TEVA
$37.3B
$10.2M 1.07%
581,940
+296,611
+104% +$6.67M
THC icon
34
Tenet Healthcare
THC
$16.8B
$10.1M 1.06%
616,796
+288,290
+88% +$4.89M
ABBV icon
35
AbbVie
ABBV
$450B
$9.13M 0.96%
102,777
-11,797
-10% -$898K
VRTX icon
36
Vertex Pharmaceuticals
VRTX
$123B
$9.09M 0.95%
59,800
-8,600
-13% -$1.29M
AET
37
DELISTED
Aetna Inc
AET
$9.02M 0.94%
56,700
+4,900
+9% +$765K
IART icon
38
Integra LifeSciences
IART
$1.5B
$8.93M 0.93%
176,850
+16,500
+10% +$847K
CI icon
39
Cigna
CI
$74.5B
$8.91M 0.93%
47,650
-27,850
-37% -$4.96M
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$35.7B
$8.88M 0.93%
75,593
-49,436
-40% -$4.22M
MNK
41
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$8.6M 0.9%
229,983
+45,038
+24% +$1.79M
LH icon
42
Labcorp
LH
$23.2B
$8.26M 0.86%
63,648
+3,853
+6% +$514K
MGNX icon
43
MacroGenics
MGNX
$285M
$8.01M 0.84%
433,299
+116,881
+37% +$2.02M
HUM icon
44
Humana
HUM
$48B
$7.64M 0.8%
31,350
+4,850
+18% +$1.19M
BCR
45
DELISTED
CR Bard Inc.
BCR
$7.29M 0.76%
22,740
-14,550
-39% -$4.65M
IQV icon
46
IQVIA
IQV
$34.4B
$6.77M 0.71%
71,170
+4,650
+7% +$431K
LGND icon
47
Ligand Pharmaceuticals
LGND
$6.08B
$6.63M 0.69%
78,066
-23,564
-23% -$1.87M
SHPG
48
DELISTED
Shire pic
SHPG
$6.5M 0.68%
42,440
-11,445
-21% -$1.79M
HZNP
49
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.17M 0.65%
486,463
+79,065
+19% +$1.01M
COO icon
50
Cooper Companies
COO
$14B
$5.69M 0.6%
96,000
– –
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2017 Portfolio in Review

As of Q3 2017, Bellevue Group held 136 positions worth $956M, up 13% from $846M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Bellevue Group deployed $88M of net new capital in Q3 2017, opening 4 new positions and adding to 63 existing holdings. Its largest new stake was Henry Schein: 48,450 shares worth $3.12M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Medtronic, an estimated $7.35M trimmed.

  • Bellevue Group's largest Q3 2017 buy was Henry Schein: 48,450 shares worth $3.12M.
  • Bellevue Group added most to Illumina in Q3 2017, an estimated $10.5M increase.
  • Bellevue Group's biggest Q3 2017 reduction was Medtronic, cutting an estimated $7.35M.
  • Bellevue Group fully exited China Biologic Products Holdings, Inc. in Q3 2017, selling an estimated $4.1M.
  • Bellevue Group's ten largest holdings make up 34% of its $956M portfolio in Q3 2017.
  • Bellevue Group opened 4 new positions and closed 5 in Q3 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $956M.

Based on Bellevue Group's 13F filing for Q3 2017, filed 13 Nov 2017.